Empagliflozin
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
Empagliflozin, sold under the brand name Jardiance, among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes. See also [https://en.wikipedia.org/wiki/Empagliflozin Empagliflozin]. | Empagliflozin, sold under the brand name Jardiance, among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes. See also [https://en.wikipedia.org/wiki/Empagliflozin Empagliflozin]. | ||
| - | Empagliflozin is an inhibitor of the | + | Empagliflozin is an inhibitor of the [[Sodium/glucose cotransporter]] (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic components in the kidneys. SGLT-2 accounts for about 90 percent of glucose reabsorption into the blood. Blocking SGLT-2 reduces blood glucose by blocking glucose reabsorption in the kidney and thereby excreting glucose (i.e., blood sugar) via the urine.<ref name="a27">PMID:18996802</ref><ref name="a28">PMID:19892839</ref><ref name="a29">PMID:19232040</ref> |
<scene name='10/1025379/Cv/2'>Human SGLT2-MAP17 complex bound with empagliflozin</scene> ([[7vsi]]). | <scene name='10/1025379/Cv/2'>Human SGLT2-MAP17 complex bound with empagliflozin</scene> ([[7vsi]]). | ||
Current revision
| |||||||||||
References
- ↑ Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008 Sep;14(6):782-90. PMID:18996802 doi:10.4158/EP.14.6.782
- ↑ Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010 Jan;95(1):34-42. PMID:19892839 doi:10.1210/jc.2009-0473
- ↑ Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009 Mar;25(3):671-81. PMID:19232040 doi:10.1185/03007990802710422
